

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

KMRC-1

RRID:CVCL_2983

Type: Cell Line

Proper Citation

RRID:CVCL_2983

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2983

Proper Citation: RRID:CVCL_2983

Description: Cell line KMRC-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Clear cell renal cell carcinoma

Defining Citation: [PMID:20215515](#), [PMID:22185343](#), [PMID:22460905](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28489074](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KMRC-1

Synonyms: KMRC1

Cross References: CLO:CLO_0009977, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:620, BioSample:SAMN03470891, BioSample:SAMN10988368, cancercellines:CVCL_2983, Cell_Model_Passport:SIDM00611, Cosmic:1995470, Cosmic-CLP:1298168, DepMap:ACH-000684, EGA:EGAS00001000978, GDSC:1298168, GEO:GSM827174, GEO:GSM887216, GEO:GSM888290, GEO:GSM1669992, IARC_TP53:30098, JCRB:JCRB1010, JCRB:NIHS0271, LiGeA:CCLE_854, LINCS_LDP:LCL-1775, PharmacDB:KMRC1_758_2019, PRIDE:PXD030304, Progenetix:CVCL_2983,

Wikidata:Q54900153

ID: CVCL_2983

Record Creation Time: 20220427T220705+0000

Record Last Update: 20260829T234420+0000

Ratings and Alerts

No rating or validation information has been found for KMRC-1.

Warning: Discontinued: JCRB; NIHS0271

Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Garinet S, et al. (2026) Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma. The Journal of clinical investigation, 136(3).

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. Cancer research communications, 5(1), 24.

Schiele P, et al. (2025) CD8+ T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells. Science advances, 11(21), eadr9331.

Garinet S, et al. (2025) Detection and monitoring of translocation renal cell carcinoma via plasma cell-free epigenomic profiling. bioRxiv : the preprint server for biology.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Takahashi M, et al. (2023) Insulin receptor expression to predict resistance to axitinib and elucidation of the underlying molecular mechanism in metastatic renal cell carcinoma. British journal of cancer, 129(3), 521.